Prognostic value of dual-time-point 18F-fluorodeoxyglucose PET/CT in metastatic breast cancer: An exploratory study of quantitative measures

4Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

This study aimed to compare the prognostic value of quantitative measures of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography (FDG-PET/CT) for the response monitoring of patients with metastatic breast cancer (MBC). In this prospective study, 22 patients with biopsy-verified MBC diagnosed between 2011 and 2014 at Odense University Hospital (Denmark) were followed up until 2019. A dual-time-point FDG-PET/CT scan protocol (1 and 3 h) was applied at baseline, when MBC was diagnosed. Baseline characteristics and quantitative measures of maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), corrected SUVmean (cSUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and corrected TLG (cTLG) were collected. Survival time was analyzed using the Kaplan-Meier method and was regressed on MTV, TLG, and cTLG while adjusting for clinicopathological characteristics. Among the 22 patients included (median age: 59.5 years), 21 patients (95%) died within the follow-up period. Median survival time was 29.13 months (95% Confidence interval: 20.4-40 months). Multivariable Cox proportional hazards regression analyses of survival time showed no influence from the SUVmean, cSUVmean, or SUVmax, while increased values of MTV, TLG, and cTLG were significantly associated with slightly higher risk, with hazard ratios ranging between 1.0003 and 1.004 (p = 0.007 to p = 0.026). Changes from 1 to 3 h were insignificant for all PET measures in the regression model. In conclusion, MTV and TLG are potential prognostic markers for overall survival in MBC patients.

References Powered by Scopus

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

23786Citations
N/AReaders
Get full text

Diagnosis of bone metastases: A meta-analysis comparing <sup>18</sup>FDG PET, CT, MRI and bone scintigraphy

281Citations
N/AReaders
Get full text

Positron emission tomography (PET) in oncology

247Citations
N/AReaders
Get full text

Cited by Powered by Scopus

FDG PET/CT Volume-Based Quantitative Data and Survival Analysis in Breast Cancer Patients: A Systematic Review of the Literature

17Citations
N/AReaders
Get full text

Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor

5Citations
N/AReaders
Get full text

Prognostic value of thoracic tumor staging and volume parameters in non-small cell lung cancer patients with synchronous solitary bone metastasis

4Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Naghavi-Behzad, M., Petersen, C. B., Vogsen, M., Braad, P. E., Hildebrandt, M. G., & Gerke, O. (2020). Prognostic value of dual-time-point 18F-fluorodeoxyglucose PET/CT in metastatic breast cancer: An exploratory study of quantitative measures. Diagnostics, 10(6). https://doi.org/10.3390/diagnostics10060398

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

60%

Immunology and Microbiology 1

20%

Neuroscience 1

20%

Save time finding and organizing research with Mendeley

Sign up for free